Trump's Executive Order to Reclassify Marijuana: A Game Changer for Medicinal Research

President Trump plans to sign an executive order to reclassify marijuana, moving it from Schedule I to Schedule III, therefore easing restrictions on medical research and drug development. This shift could facilitate FDA approvals and accelerate research on cannabinoid drugs for various medical conditions.

In a significant move, President Donald Trump is poised to sign an executive order reclassifying marijuana within federal law. This order aims to shift marijuana from Schedule I to Schedule III under the U.S. Controlled Substances Act, aligning it with substances like codeine and morphine.

The reclassification is anticipated to reduce the hurdles faced by researchers seeking funds and pharmaceutical companies aiming for FDA approvals for medical marijuana-derived products. This realignment could significantly promote research and the development of new cannabinoid-based medications.

Historically deemed federally illegal, marijuana's new classification may still bar commercial sale without FDA endorsement but promises lighter penalties. Advocates argue that this change could lead to breakthroughs in treatment for various medical conditions including chronic pain, sleep apnea, and multiple sclerosis.

(With inputs from agencies.)